Wrapping up Q4 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including Insulet ...

Stelo by Dexcom is the first over-the-counter continuous glucose monitor (CGM) in the U.S. Though specifically designed for people with prediabetes or type 2 diabetes who don’t use insulin, anyone 18 ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

Dexcom VP, Medical Affairs, Dr. Jessica Castle. [Image from LinkedIn] At ATTD 2026, Dexcom (Nasdaq:DXCM) outlined a range of ways in which its continuous glucose monitors (CGMs) benefit people with ...

A man wears the Dexcom G7 on his arm while taking photographs. [Image courtesy of Dexcom] Diabetes technology innovators gathered in Barcelona last week for the 19th annual Advanced Technologies and ...

Dexcom are phasing out their Dexcom G6 continuous glucose monitor (CGM) and replacing it with the Dexcom G7.

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong fourth-quarter 2025 ...

According to Dexcom, the company’s new data emphasises the case to expand its CGM for people with all types of diabetes. Credit: Michael Vi / Shutterstock.com Dexcom is poised to share new data on the ...

BARCELONA, Spain--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for ...

I’ve contributed to PCMag since 2019, covering all kinds of consumer electronics. As a self-identifying early adopter of technology, I’ve stumbled through the changing devices over the years and ...